Answers are grounded in this paper and cite their sources.
Patent review reveals advancing delivery strategies bypassing the blood-brain barrier for neurodegenerative disorders, indicating accelerated pathways toward targeted clinical translation.
INTRODUCTION: The blood-brain barrier (BBB) restricts drug entry into the CNS, with most therapeutics showing < 1% brain penetration, limiting efficacy in neurodegenerative diseases. AREAS COVERED: Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain barrier,' 'brain delivery,' and neurodegenerative disease terms. Technologies were included if supported by in vitro or in vivo BBB‑penetration evidence for neurodegenerative indications; purely computational, non‑English untranslated, and non‑targeted conventional formulation patents were excluded. Eligible patents were classified into protein/antibody‑based, small molecule, nanocarrier, physical‑assisted, permeability enhancer, and emerging technology categories. EXPERT OPINION: Receptormedia-ted transcytosis, dual-targeting ligands, and ultrasound opening are enhancing delivery precision; emerging systems (small molecules, peptides, nanozymes) combine penetration with target inhibition, overcoming traditional bottlenecks and accelerating clinical translation.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: